United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $572.38, for a total transaction of $4,579,040.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $23,188,830.94. This represents a 16.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Trading Down 1.3%

Shares of NASDAQ:UTHR traded down $7.68 during trading on Wednesday, hitting $570.75. 314,854 shares of the company’s stock were exchanged, compared to its average volume of 479,013. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a 50-day moving average price of $564.81 and a two-hundred day moving average price of $513.93. The firm has a market cap of $24.23 billion, a P/E ratio of 21.07, a PEG ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 EPS. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its stake in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares in the last quarter. Bull Harbor Capital LLC bought a new position in United Therapeutics in the first quarter valued at approximately $494,000. Strategic Investment Advisors MI lifted its stake in United Therapeutics by 20.5% in the first quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after buying an additional 1,662 shares in the last quarter. Talon Private Wealth LLC bought a new position in United Therapeutics in the first quarter valued at approximately $3,038,000. Finally, Royal Bank of Canada lifted its stake in United Therapeutics by 3.3% in the first quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock valued at $35,075,000 after buying an additional 1,864 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.